Cerebral Artery Syndrome Treatment Market Size & Share, by Treatment (Surgery, Medication); Surgery Type (Carotid Endarterectomy, Angioplasty, Bypass Surgery); Distribution Channel (Hospital, Specialty Clinic, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3463
  • Published Date: Jan 01, 2024
  • Report Format: PDF, PPT

Companies Dominating the Cerebral Artery Syndrome Treatment Landscape

top-features-companies
    • Bristol Myers Squibb
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Athersys, Inc.
    • Janssen Pharmaceuticals, Inc
    • Royal Philips
    • AstraZeneca plc

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • The FDA has granted Fast Track Designation for all three of the potential Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen), announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor, have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexiadevelopment program, which are all dosing patients. indications of milvexian, an investigational oral factor XIa (FXIa) inhibitor, to Bristol Myers Squibb (NYSE: BMY) in partnership with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen).
  • Following a Type B meeting with the U.S. Food & Drug Administration (FDA), Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine firm developing MultiStem® (invimestrocel) for critical care applications, announced proposed modifications to its MASTERS-2 clinical trial protocol. The meeting, which took place on March 21, 2023, covered the standard of care as well as Athersys' proposed modifications, which aim to establish primary and secondary endpoints that best reflect the company's belief of the full potential benefit of MultiStem treatment for patients with acute, moderate-to-severe ischemic stroke.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3463
  • Published Date: Jan 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing research and development activities, rising technological advancements in healthcare industry, and increasing awareness among the individuals are the major factors driving the growth of the cerebral artery syndrome treatment market.

The market size of cerebral artery syndrome treatment is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market are Bristol Myers Squibb, Athersys, Inc., Janssen Pharmaceuticals, Inc, Royal Philips, AstraZeneca plc, Daiichi Sankyo Company, Limited, LIFESCAPES Inc, Shionogi & Co., Ltd., Fujitsu, Takeda Pharmaceutical Co Ltd and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying